Ligand Pharmaceuticals (NASDAQ:LGND) Given New $250.00 Price Target at Oppenheimer

Ligand Pharmaceuticals (NASDAQ:LGND) Given New $250.00 Price Target at Oppenheimer

Ligand Pharmaceuticals (NASDAQ:LGND – Free Report) had its price objective hoisted by Oppenheimer from $190.00 to $250.00 in a report issued on Monday,Benzinga reports. They currently have an outperform rating on the biotechnology company’s stock. LGND has been the subject of several other research reports. Benchmark raised their price objective on Ligand Pharmaceuticals from $160.00 to $175.00 and gave the company a “buy” rating in a research r…